[go: up one dir, main page]

MX2009010066A - Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer. - Google Patents

Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.

Info

Publication number
MX2009010066A
MX2009010066A MX2009010066A MX2009010066A MX2009010066A MX 2009010066 A MX2009010066 A MX 2009010066A MX 2009010066 A MX2009010066 A MX 2009010066A MX 2009010066 A MX2009010066 A MX 2009010066A MX 2009010066 A MX2009010066 A MX 2009010066A
Authority
MX
Mexico
Prior art keywords
targeted
compositions
methods
cancer
ablation
Prior art date
Application number
MX2009010066A
Other languages
English (en)
Inventor
David Apelian
Alex Franzusoff
Timothy C Rodell
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of MX2009010066A publication Critical patent/MX2009010066A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en la presente composiciones y métodos para la ablación específica de evasión mutacional de frente a agentes terapéuticos anti-cáncer. Las composiciones comprenden vehículos con base de levadura que se utilizan en combinación con otros agentes terapéuticos anti-cáncer.
MX2009010066A 2007-03-19 2008-01-17 Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer. MX2009010066A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89568907P 2007-03-19 2007-03-19
US91079607P 2007-04-09 2007-04-09
PCT/US2008/051348 WO2008115610A1 (en) 2007-03-19 2008-01-17 Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer

Publications (1)

Publication Number Publication Date
MX2009010066A true MX2009010066A (es) 2009-10-12

Family

ID=39575570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010066A MX2009010066A (es) 2007-03-19 2008-01-17 Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.

Country Status (13)

Country Link
US (1) US8501167B2 (es)
EP (1) EP2134358A1 (es)
JP (2) JP5579451B2 (es)
KR (1) KR20100015661A (es)
CN (1) CN101730542A (es)
AU (1) AU2008229295B2 (es)
BR (1) BRPI0809247A2 (es)
CA (1) CA2681246A1 (es)
IL (1) IL201039A0 (es)
MX (1) MX2009010066A (es)
NZ (1) NZ580444A (es)
RU (1) RU2505313C2 (es)
WO (1) WO2008115610A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
CN102614510A (zh) 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
CN101262883A (zh) * 2005-07-11 2008-09-10 环球免疫公司 引发针对靶向的疗法的逃逸突变体的免疫应答的组合物和方法
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune Inc mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
US10383924B2 (en) 2009-04-17 2019-08-20 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
AU2012214394B2 (en) 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
CA2838950C (en) 2011-06-14 2020-10-27 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
WO2014003853A1 (en) 2012-06-26 2014-01-03 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014024965A1 (ja) * 2012-08-10 2014-02-13 学校法人 久留米大学 上皮成長因子受容体のt790m点突然変異配列に由来する抗原ペプチド
CA2907560C (en) 2013-03-19 2021-12-07 Timothy C. Rodell Yeast-based immunotherapy for chordoma
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
WO2015157639A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
CA3018748A1 (en) * 2016-03-31 2017-10-05 Neon Therapeutics, Inc. Neoantigens and methods of their use
CA3058807A1 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN112543640B (zh) 2018-05-15 2025-02-14 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
CN112767998B (zh) * 2019-01-29 2024-10-08 杭州纽安津生物科技有限公司 针对靶向药物达拉菲尼、派姆单抗、威罗菲尼、司美替尼的多肽疫苗组合及其设计方法
CN116536402B (zh) * 2023-03-08 2025-06-24 华中科技大学同济医学院附属协和医院 Arms-pcr法检测bcr-abl融合基因abl激酶区的核酸组合物、试剂盒

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) * 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) * 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
CA2560114A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5871986A (en) * 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5676950A (en) * 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
US6107457A (en) * 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US6258595B1 (en) * 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ATE319475T1 (de) * 2000-04-06 2006-03-15 Seer Pharmaceuticals Llc Microbielles wirkstoffabgabesystem
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
CA2450692A1 (en) * 2001-06-12 2003-01-30 Kyogo Itoh Tumor antigen
EP2322628B1 (en) * 2001-06-14 2017-03-15 The Regents of The University of California Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571
US20050074463A1 (en) * 2001-09-14 2005-04-07 Universite Pierre Et Marie Curie-Paris Vi Therapeutic vaccination method, mutated peptides of hiv reverse transciptase and their use for vaccination and diagnostic purposes
US20030170851A1 (en) * 2001-10-05 2003-09-11 Christophe Barthe Organic compounds
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
JP4765273B2 (ja) * 2004-06-23 2011-09-07 三菱化学株式会社 ポリエステル系樹脂の分解処理方法
WO2006039533A2 (en) * 2004-09-30 2006-04-13 Sloan Kettering Institure For Cancer Research Bcr-abl imatinib resistance-associated peptides and methods of use thereof
CN102614510A (zh) * 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
CN101262883A (zh) * 2005-07-11 2008-09-10 环球免疫公司 引发针对靶向的疗法的逃逸突变体的免疫应答的组合物和方法
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
KR20140029551A (ko) * 2006-02-02 2014-03-10 글로브이뮨 면역 반응 유도를 위한 효모-기반 백신
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune Inc mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
JP5570819B2 (ja) * 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
US10383924B2 (en) 2009-04-17 2019-08-20 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
EP2547792A4 (en) 2010-03-14 2013-11-27 Globeimmune Inc PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY

Also Published As

Publication number Publication date
JP5579451B2 (ja) 2014-08-27
IL201039A0 (en) 2010-05-17
AU2008229295B2 (en) 2014-05-22
WO2008115610A1 (en) 2008-09-25
RU2009138327A (ru) 2011-04-27
KR20100015661A (ko) 2010-02-12
JP2014156467A (ja) 2014-08-28
NZ580444A (en) 2012-02-24
US20100111912A1 (en) 2010-05-06
BRPI0809247A2 (pt) 2014-09-09
JP2010522180A (ja) 2010-07-01
EP2134358A1 (en) 2009-12-23
RU2505313C2 (ru) 2014-01-27
AU2008229295A1 (en) 2008-09-25
CA2681246A1 (en) 2008-09-25
US8501167B2 (en) 2013-08-06
CN101730542A (zh) 2010-06-09

Similar Documents

Publication Publication Date Title
MX2009010066A (es) Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
TW200738263A (en) ANG2 and VEGF inhibitor combinations
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
WO2009054996A3 (en) Systems and methods for viral therapy
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
SG164368A1 (en) Treatment of cancer
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
WO2008030883A3 (en) Treatment of cancer
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
EP2214495A4 (en) NATURALLY PHOTODYNAMIC ACTIVE SUBSTANCES AND ITS USE
WO2013061083A3 (en) Therapeutic agents and uses thereof
WO2007146983A3 (en) Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury
WO2010124283A3 (en) Methods and compositions relating to hematologic malignancies
MX2010005057A (es) Metodos y composiciones para uso de diagnostico en pacientes de cancer.
JO3262B1 (ar) توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
MX2010002667A (es) Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
MX2009013950A (es) Combinaciones antitumorales que contienen un agente inhibidor de vegf e irinotecan.

Legal Events

Date Code Title Description
FG Grant or registration